U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT07484269) titled 'PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan' on March 16.
Brief Summary: The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer
Study Start Date: Aug. 01, 2026
Study Type: OBSERVATIONAL
Condition:
Metastatic Prostate Cancer
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Novartis Pharmaceuticals
Disclaimer: Curated by HT Syndication....